The review found 22 studies showed reduced amyloid-beta plaques and 19 showed reduced tau tangles, key markers of Alzheimer's disease. Only two small human trials were included, with mixed results.
Researchers highlight potential mechanisms such as reduced inflammation and improved brain insulin signaling, but emphasize that larger clinical trials are needed to confirm benefits in humans.
If semaglutide failed, could another GLP-1 drug still succeed against Alzheimer's disease?
Will dementia prevention with GLP-1 drugs become a luxury only for the wealthy?
Beyond weight loss, what are the hidden long-term neurological risks of these drugs?
Is Alzheimer's really 'Type 3 diabetes,' and can managing blood sugar save our brains?
With conflicting studies, should people start taking Ozempic to prevent dementia?